Protocols
21 protocol(s) meet the specified criteria
Disease Site: Brain and Nervous System
Protocol No.TitleStatus
A071401-CIRBPhase II Trial of SMO/AKT/NF2 inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations Open
CA209-204Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab MonotherapyOpen
COG-ACNS0831Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 yearsOpen
COG-ACNS1123Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)Open
COG-ANBL1221A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive NeuroblastomaOpen
COG-ANBL1232Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaOpen
COGACNS0332Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients Open
D419LC00001A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer PatientsOpen
D6410C00001A Phase I, First-Time-in Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with Solid Tumor CancerOpen
LCCC1308Engineering Reprogrammed Patient-derived Neural Stem Cells for Novel Malignant Glioma TherapyOpen
LCCC1419Establishment of Breast Cancer Brain Metastases (BCBM) Registry to Support Research of Molecular Drivers of BCBMOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1540Prospective Evaluation of Patient-Reported Xerostomia After Whole Brain Radiation.Open
LCCC1602Health services use and social outcomes of adult survivors of childhood cancerOpen
LOXO-TRK-15002A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive TumorsOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
N107C-CIRBN107C, A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain DiseaseOpen (affiliates only)
NRG-CC001A randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in patients with Brain Metastases Open
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
VEG116731A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid TumorsOpen